Effects of l-dopa/carbidopa administration on the levels of l-dopa, other amino acids and related compounds in the plasma, brain and heart of the rat

Pharmacology

Volumn 55, Issue 3, 1997, Pages 109-116

  Diederich, Christian ^a   Milakofsky, Louis ^a,b   Hare, Theodore A ^a   Hofford, James M ^a   Dadmarz, Mitra ^a   Vogel, Wolfgang H ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Amino acids; Amino compounds; Brain; Carbidopa; Heart; L DOPA; Parkinson s disease; Plasma

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE; AMINO ACID; AMMONIA; ARGININE; ASPARAGINE; CARBIDOPA; CARNOSINE; CITRULLINE; DOPAMINE; ETHANOLAMINE; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLYCINE; HISTIDINE DERIVATIVE; HOMOCARNOSINE; LEUCINE; LEVODOPA; LYSINE; ORNITHINE; PHENYLALANINE; PHOSPHOSERINE; SERINE; TAURINE; THREONINE; TYROSINE; VALINE;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN CORTEX; BRAIN LEVEL; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030809589     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139518     Document Type: Article

References (32)

1. Plctschcr A. DaPrada M: Pharmacotherapy of Parkinson's disease: Research from 1960 to 1991. Acta Neurol Scand 1993(suppl 146):26-31.
2. Ahlskog JE: Treatment of Parkinson’s disease. From theory to practice. Postgrad Med 1994:95:52-54. 57-58,61-64.
3. Aminof TMJ: Treatment of Parkinson's disease. West J Med 1994:161: 303-308.
4. Mizuno Y: Drug therapy of Parkinson's disease. An overview. Eur Neurol 1992;32(suppl 1):3-8.
5. Caine DB: Treatment of Parkinson’s disease. N Engl J Med 1993:329: 1021-1027.
6. Leskow P. Lachcnmaycr L: Parkinson therapy yesterday, today, tomorrow. Neuroprotection gains in importance. Fortschr Med 1992:110: 589-592.
7. Bodagh IY, Robertson DR: A risk-benefit assessment of drugs used in the management of Parkinson’s disease. Drug Saf 1994:11:94-103.
8. Weiss BF. Munro UN, Wurtman RJ: -DOPA: Disaggregation of brain polysomes and elevation of brain tryptophan. Science 1971:173: 833-835.
9. Wade LA. Katzman R: Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J Neurochem 1975:25:837-842.
10. Wurtman RJ. Ordonez LA: Effects of exogenous L-DOPA on the metabolism of methionine and S-ade-nosylmcthionine in the brain. Mon-ogr Gcsamtgeb Psychiatr (Berlin) 1978;18:132-143.
11. Nutt JG, Woodward WR. Carter JH, Trotman TL: Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989;52: 481-487.
12. Lehninger AL, Nelson DC, Michael MC: Principles of Biochemistry, ed 2. New York. Worth. 1993. pp 198-239.
13. Cummings JL: Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-716.
14. Heaficld MT, Williams AC: Parkinson’s disease: Clinical and therapeutic aspects. Opin Neurol Neurosurg 1992:5:288-294.
15. Saint-Cyr JA. Taylor AE, Lang AE: Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993: 43(suppl 6):47-52.
16. Milakofskv L. Hare TA. Miller JM. Vogel WH: Comparison of amino acid levels in rat blood obtained by catheterization and decapitation. Life Sci 1984:34:1333-1340.
17. Hare TA, Vogel WH: Rapid estimation of Dopa in physiologial fluids using the amino acid analyzer. Bio-chemMed 1970;4:277-281.
18. Fahn S, Snider S, Prasad ALN. Lane E, Makadon H: Normalization of brain serotonin by /-tryptophan in levodopa-trcated rats. Neurology 1975:25:861-865.
19. Eriksson T. Grancrus AK, Linde A, Carlsson A: ‘On-off phenomenon in Parkinson's disease: Relationship between dopa and other large neutral amino acids in plasma. Neurology 1988;38:1245-1248.
20. Mizuta E. Kuno S: Rotations induced by L-Dopa in parkonsonian rats are reduced by an ingestion of amino acids. J Neural Transam Park Dis Dement Sect 1993;6:211-214.
21. Woodward WR, Olanow CW, Beckner RM. Hauser RA, Gauger LL, Ccdarbaum JM. Nutt JG: The effect of L-Dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. Neurology 1993: 43:1704-1708.
22. Algcri S. Cerlctti C: Effects of LDopa administration on the serotonergic system in rat brain: correlation between levels of L-Dopa accumulated in the brain and depiction of serotonin and tryptophan. Eur J Pharmacol 1974;27:191-197.
23. Karobath M. Diaz J-L. Huttunen MO: The effect of ¿-DOPA on the concentrations of tryptophan, tyrosine and serotonin in rat brain. Eur J Pharmacol 1971:14:393-396.
24. Wurtman RJ: Effect of L-Dopa on S-adenosylmethioninc levels and norepinephrine metabolism in rat brain. Adv Biochem Psychopharma-col 1972;6:241-246.
25. Taufck HR. Bone AH: Influence of exogenous L-3,4-dihydroxyphenyl-alaninc (L-DOPA) on the methionine and S-adenosylmcthionine concentrations in the brain and other tissues. Biochcm Soc Trans 1980: 8:62-63.
26. Nicklas WJ. Berl S. Clarke DD: Interaction of catecholamine and amino acid metabolism in brain: effect of pargyline and L-dopa. J Neurochem 1974:23:149-157.
27. Lloyd KG, Homykiewicz O: Effect of chronic neuroleptic or ¿-dopa administration on GABA levels in the rat substantia nigra. Life Sci 1977: 21:1489-1496.
28. Zanchin G. Rigotti P, Dussini N, Bettineschi F, Vassanelli P. Battistin L: Effect of L-DOPA treatment on cerebral amino acid levels in rats after portocaval anastomosis. Ncu-rochem Res 1981:6:649-658.
29. Hare TA. Vanna S. Beasley B, Chambers R, Vogel WH: Amino acid and dopa levels in plasma and urine from L-DOPA treated patients with Parkinson's disease. J Lab Clin Med 1971;77:319-325.
30. Ossowska K: The role of excitatory amino acids in experimental models of Parkinson's disease. J Neural Transm Park Dis Dement Sect 1994;8:39-71.
31. Manyam BV, Ferraro TN, Hare TA: Cerebrospinal fluid amino compounds in Parkinson's disease. Arch Neurol 1988:45:48-50.
32. Bednar I. Baig S, Silberring J. Slen-fors C, Sodcrstcn P, Siden A, Qure-shi GA: Excitatory amino acids, monoamines, neuropeptide Y and cholecystokinin in cerebrospinal fluid of Parkinson patients. Biogenic Amines 1996:12:275-284.